Silver Book Fact

TAVR improves quality of life in SAS patients

Fact image

Kovac J, Schuler G, Gerckens U, Muller R, et al. Four-Year Experience with CoreValve Transcatheter Heart Valve. EuroInterven. 2016; 12(8). https://pubmed.ncbi.nlm.nih.gov/27159659/

Reference

Title
Four-Year Experience with CoreValve Transcatheter Heart Valve
Publication
EuroInterven
Publication Date
2016
Authors
Kovac J, Schuler G, Gerckens U, Muller R, et al.
Volume & Issue
Volume 12, Issue 8
Pages
1039-46
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Cost-effectiveness of TAVR in sSAS patients
    Patients with severe symptomatic aortic stenosis (sSAS) considered to be at high surgical risk who underwent transcatheter aortic valve replacement (TAVR) experienced lifetime incremental cost-effectiveness ratios of $55,090 per QALY…  
  • Surgical Aortic Valve Replacements in 2010
    In 2010, ~67,500 surgical aortic valve replacements (SAVR) were performed in the U.S.  
  • Survival rates of SAS patients ages 80+ with and without SAVR
     
  • TAVR v. SAVR in Intermediate-Risk SAS Patients
    At 1-year, severe aortic stenosis (SAS) patients with intermediate surgical mortality risk who underwent transcatheter aortic valve replacement (TAVR), had all-cause mortality rates of 7.4% (compared to 13% for surgical…  
  • TAVR Success in sSAS Patients
    A study of severe symptomatic aortic stenosis (sSAS) patients who received transcatheter aortic valve replacement (TAVR) found 30-day mortality of 2.2% for those who were high risk of surgical mortality/inoperable,…